Table 1

PODXL expression and clinicopathological parameters of the cohort
PODXL neg PODXL pos
n (%) 73 (100) 55 (75,3) 18 (24,7) p-value
Age
≤75 49 (67,1) 36 (65,5) 13 (72,2) 0.77
>75 24 (32,9) 19 (34,5) 5 (27,8)
Gender
Female 36 (49,3) 20 (36,4) 16 (88,9) <0,001
Male 37 (50,7) 35 (63,6) 2 (11,1)
T
1 2 (2,7) 1 (1,8) 1 (5,6) 0.62
2 13 (17,8) 11 (20,0) 2 (11,1)
3 46 (63,0) 35 (63,6) 11 (61,1)
4 12 (16,4) 8 (14,5) 4 (22,2)
N
0 40 (54,8) 34 (61,8) 6 (33,3) 0.09
1 21 (28,8) 14 (25,5) 7 (38,9)
2 12 (16,4) 7 (12,7) 5 (27,8)
M
0 69 (94,5) 52 (94,5) 17 (94,4) 0.99
1 4 (5,5) 3 (5,5) 1 (5,6)
Stage
I 11 (15,1) 9 (16,4) 2 (11,1) 0.24
II 28 (38,4) 24 (43,6) 4 (22,2)
III 30 (41,1) 19 (34,5) 11 (61,1)
IV 4 (5,5) 3 (5,5) 1 (5,6)
Diff grade
Intermed-high 58 (79,4) 48 (87,3) 10 (55,6) 0.02
Low 14 (19,2) 7 (12,7) 7 (38,9)
Missing 1 (1,4) 1 (5,6)
Mucinous histology
Absent 63 (86,3) 51 (92,7) 12 (66,7) 0.01
Present 10 (13,7) 4 (7,3) 6 (33,3)
Vascular invasion
Absent 57 (78,1) 45 (81,8) 12 (66,7) 0.2
Present 16 (21,9) 10 (18,2) 6 (33,3)
Neural invasion
Absent 67 (91,8) 52 (94,5) 15 (83,3) 0.16
Present 6 (8,2) 3 (5,5) 3 (16,7)
Location
Colon 40 (54,8) 28 (50,9) 12 (66,7) 0.29
Rectum 33 (45,2) 27 (49,1) 6 (33,3)
Neoadj radiation (n=33)1
25 Gy 18 (54,5) 14 (51,8) 4 (66,7) 0.91
50,4 Gy + cap 3 (9,1) 2 (7,4) 1 (16,7)
No 12 (36,4) 11 (40,7) 1 (16,7)
Adj treatment
Yes 19 (26,0) 8 (14,5) 11 (61,1) <0,001
No 54 (74,0) 47 (85,5) 7 (38,9)

1Rectal cancer patients only.

Larsson et al.

Larsson et al. Diagnostic Pathology 2013 8:109   doi:10.1186/1746-1596-8-109

Open Data